PMID- 21419003
OWN - NLM
STAT- MEDLINE
DCOM- 20111115
LR  - 20110322
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 91
IP  - 5
DP  - 2011 Feb 1
TI  - [Clinical characteristics of highly active antiretroviral therapy-associated 
      immune reconstruction inflammation in acquired immunodeficiency syndrome].
PG  - 304-8
AB  - OBJECTIVE: To summarize the morbidity, mortality, clinical manifestations and 
      risk factors for IRIS (immune reconstruction inflammatory syndrome) during HAART 
      (highly active antiretroviral therapy) in China. METHODS: From October 2007 to 
      September 2009, a prospective cohort of 238 AIDS (acquired immunodeficiency 
      syndrome) patients on HAART from Hunan and Jianxi provinces was recruited for a 
      follow-up of 24 weeks. And 47 and 191 patients were assigned into the IRIS and 
      non-IRIS groups respectively. The data of general information, clinical 
      manifestations and treatment of two groups were collected and compared. Blood 
      samples were collected in both groups at pre-and post-HAART 12 weeks, 24 weeks 
      for HIV viral load and CD4(+) cell count examinations. A statistical analysis was 
      performed. RESULTS: A total of 47 (19.7%) IRIS cases was analyzed. The median 
      onset of IRIS was 28 (9 - 36) days. And 29 (61.7%) cases of tuberculosis IRIS 
      were found. There was no significant difference in age, gender, route of 
      transmission and antiretroviral regimens between the IRIS and non-IRIS groups. At 
      baseline, Weeks 12 and 24, both groups showed a significant decline of viral 
      load. And there was no significant difference between them. Both groups showed a 
      significant increase of CD4(+) cell count. But there was no significant 
      difference between two groups. However, the baseline CD4(+) cell count was 
      markedly lower in the IRIS group than that in the non-IRIS group. In 85.1% 
      (40/47) of cases, the CD4(+) cell count was < 100 x 10(6)/L in the IRIS group at 
      the baseline of HAART. CONCLUSION: IRIS mostly occurs during 3 months of HAART 
      initiation. The age, gender, route of transmission and antiretroviral treatment 
      regimens of patients on HAART are not risk factors for the development of IRIS. 
      The HIV RNA viral load decreases in both IRIS and non-IRIS groups without any 
      significant difference. The patients with a CD4(+) cell count < 100/microl are more 
      vulnerable to develop IRIS.
FAU - Liu, Meng
AU  - Liu M
AD  - AIDS Research Laboratory, Second Xiangya Hospital, Central South University, 
      Changsha 410011, China.
FAU - Zheng, Yu-Huang
AU  - Zheng YH
FAU - Zhou, Guo-Qiang
AU  - Zhou GQ
FAU - Zhou, Hua-Ying
AU  - Zhou HY
FAU - Chen, Zi
AU  - Chen Z
FAU - He, Yan
AU  - He Y
FAU - Chen, Xia
AU  - Chen X
FAU - Zheng, Li-Wen
AU  - Zheng LW
FAU - Jia, Lu
AU  - Jia L
FAU - He, Mei
AU  - He M
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
SB  - IM
MH  - Acquired Immunodeficiency Syndrome/drug therapy
MH  - Adult
MH  - Antiretroviral Therapy, Highly Active/*adverse effects
MH  - Female
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*diagnosis/*etiology
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Risk Factors
MH  - Viral Load
EDAT- 2011/03/23 06:00
MHDA- 2011/11/16 06:00
CRDT- 2011/03/23 06:00
PHST- 2011/03/23 06:00 [entrez]
PHST- 2011/03/23 06:00 [pubmed]
PHST- 2011/11/16 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2011 Feb 1;91(5):304-8.